Publication
Thrombotic Microangiopathy in the Renal Allograft: Results of the TMA Banff Working Group Consensus on Pathologic Diagnostic Criteria
Downloadable Content
- Persistent URL
- Last modified
- 06/17/2025
- Type of Material
- Authors
- Language
- English
- Date
- 2023-08-23
- Publisher
- Frontiers
- Publication Version
- Copyright Statement
- © 2023 Afrouzian, Kozakowski, Liapis, Broecker, Truong, Avila-Casado, Regele, Seshan, Ambruzs, Farris, Buob, Chander, Cheraghvandi, Clahsen-van Groningen, de Almeida Araujo, Ertoy Baydar, Formby, Galesic Ljubanovic, Herrera Hernandez, Honsova, Mohamed, Ozluk, Rabant, Royal, Stevenson, Toniolo and Taheri.
- License
- Final Published Version (URL)
- Title of Journal or Parent Work
- Volume
- 36
- Start Page
- 11590
- Grant/Funding Information
- This study was performed under the auspices of the Banff Foundation on Allograft Pathology and supported by grants from the Banff Foundation (for publication fees) and Alexion Pharmaceuticals (#100288).
- Supplemental Material (URL)
- Abstract
- The Banff community summoned the TMA Banff Working Group to develop minimum diagnostic criteria (MDC) and recommendations for renal transplant TMA (Tx-TMA) diagnosis, which currently lacks standardized criteria. Using the Delphi method for consensus generation, 23 nephropathologists (panelists) with >3 years of diagnostic experience with Tx-TMA were asked to list light, immunofluorescence, and electron microscopic, clinical and laboratory criteria and differential diagnoses for Tx-TMA. Delphi was modified to include 2 validations rounds with histological evaluation of whole slide images of 37 transplant biopsies (28 TMA and 9 non-TMA). Starting with 338 criteria in R1, MDC were narrowed down to 24 in R8 generating 18 pathological, 2 clinical, 4 laboratory criteria, and 8 differential diagnoses. The panelists reached a good level of agreement (70%) on 76% of the validated cases. For the first time in Banff classification, Delphi was used to reach consensus on MDC for Tx-TMA. Phase I of the study (pathology phase) will be used as a model for Phase II (nephrology phase) for consensus regarding clinical and laboratory criteria. Eventually in Phase III (consensus of the consensus groups) and the final MDC for Tx-TMA will be reported to the transplantation community.
- Author Notes
- Keywords
- Research Categories
- Health Sciences, Medicine and Surgery
Tools
- Download Item
- Contact Us
-
Citation Management Tools
Relations
- In Collection:
Items
| Thumbnail | Title | File Description | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|---|
|
|
Publication File - w9xtm.pdf | Primary Content | 2025-06-05 | Public | Download |